Text · Amendment list
Laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006
Full title
Laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006
Document ENVI-AM-756135 · COM(2023)0193 – C9-0144/2023 – 2023/0131(COD)
- Kind
- Amendment list ENVI-AM-756135
- Date
- 21 November 2023
- Committee
- Committee on the Environment, Public Health and Food Safety
- Dossier
- 2023-0131
More facts (2)
- Formats
- Official page PDF Word
- Reference
- COM(2023)0193 – C9-0144/2023 – 2023/0131(COD)
Text
The text as parsed from the official Word file. Every paragraph has a link (¶) and can be saved to a project as a passage.
Jump to an amendment (215)
- Amendment 1062
- Amendment 1063
- Amendment 1064
- Amendment 1065
- Amendment 1066
- Amendment 1067
- Amendment 1068
- Amendment 1069
- Amendment 1070
- Amendment 1071
- Amendment 1072
- Amendment 1073
- Amendment 1074
- Amendment 1075
- Amendment 1076
- Amendment 1077
- Amendment 1078
- Amendment 1079
- Amendment 1080
- Amendment 1081
- Amendment 1082
- Amendment 1083
- Amendment 1084
- Amendment 1085
- Amendment 1086
- Amendment 1087
- Amendment 1088
- Amendment 1089
- Amendment 1090
- Amendment 1091
- Amendment 1092
- Amendment 1093
- Amendment 1094
- Amendment 1095
- Amendment 1096
- Amendment 1097
- Amendment 1098
- Amendment 1099
- Amendment 1100
- Amendment 1101
- Amendment 1102
- Amendment 1103
- Amendment 1104
- Amendment 1105
- Amendment 1106
- Amendment 1107
- Amendment 1108
- Amendment 1109
- Amendment 1110
- Amendment 1111
- Amendment 1112
- Amendment 1113
- Amendment 1114
- Amendment 1115
- Amendment 1116
- Amendment 1117
- Amendment 1118
- Amendment 1119
- Amendment 1120
- Amendment 1121
- Amendment 1122
- Amendment 1123
- Amendment 1124
- Amendment 1125
- Amendment 1126
- Amendment 1127
- Amendment 1128
- Amendment 1129
- Amendment 1130
- Amendment 1131
- Amendment 1132
- Amendment 1133
- Amendment 1134
- Amendment 1135
- Amendment 1136
- Amendment 1137
- Amendment 1138
- Amendment 1139
- Amendment 1140
- Amendment 1141
- Amendment 1142
- Amendment 1143
- Amendment 1144
- Amendment 1145
- Amendment 1146
- Amendment 1147
- Amendment 1148
- Amendment 1149
- Amendment 1150
- Amendment 1151
- Amendment 1152
- Amendment 1153
- Amendment 1154
- Amendment 1155
- Amendment 1156
- Amendment 1157
- Amendment 1158
- Amendment 1159
- Amendment 1160
- Amendment 1161
- Amendment 1162
- Amendment 1163
- Amendment 1164
- Amendment 1165
- Amendment 1166
- Amendment 1167
- Amendment 1168
- Amendment 1169
- Amendment 1170
- Amendment 1171
- Amendment 1172
- Amendment 1173
- Amendment 1174
- Amendment 1175
- Amendment 1176
- Amendment 1177
- Amendment 1178
- Amendment 1179
- Amendment 1180
- Amendment 1181
- Amendment 1182
- Amendment 1183
- Amendment 1184
- Amendment 1185
- Amendment 1186
- Amendment 1187
- Amendment 1188
- Amendment 1189
- Amendment 1190
- Amendment 1191
- Amendment 1192
- Amendment 1193
- Amendment 1194
- Amendment 1195
- Amendment 1196
- Amendment 1197
- Amendment 1198
- Amendment 1199
- Amendment 1200
- Amendment 1201
- Amendment 1202
- Amendment 1203
- Amendment 1204
- Amendment 1205
- Amendment 1206
- Amendment 1207
- Amendment 1208
- Amendment 1209
- Amendment 1210
- Amendment 1211
- Amendment 1212
- Amendment 1213
- Amendment 1214
- Amendment 1215
- Amendment 1216
- Amendment 1217
- Amendment 1218
- Amendment 1219
- Amendment 1220
- Amendment 1221
- Amendment 1222
- Amendment 1223
- Amendment 1224
- Amendment 1225
- Amendment 1226
- Amendment 1227
- Amendment 1228
- Amendment 1229
- Amendment 1230
- Amendment 1231
- Amendment 1232
- Amendment 1233
- Amendment 1234
- Amendment 1235
- Amendment 1236
- Amendment 1237
- Amendment 1238
- Amendment 1239
- Amendment 1240
- Amendment 1241
- Amendment 1242
- Amendment 1243
- Amendment 1244
- Amendment 1245
- Amendment 1246
- Amendment 1247
- Amendment 1248
- Amendment 1249
- Amendment 1250
- Amendment 1251
- Amendment 1252
- Amendment 1253
- Amendment 1254
- Amendment 1255
- Amendment 1256
- Amendment 1257
- Amendment 1258
- Amendment 1259
- Amendment 1260
- Amendment 1261
- Amendment 1262
- Amendment 1263
- Amendment 1264
- Amendment 1265
- Amendment 1266
- Amendment 1267
- Amendment 1268
- Amendment 1269
- Amendment 1270
- Amendment 1271
- Amendment 1272
- Amendment 1273
- Amendment 1274
- Amendment 1275
- Amendment 1276
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The orphan medicine sponsor shall submit an application for the designation of the orphan medicinal product to the Agency at any stage of the development of the medicinal product before the application for marketing authorisation referred to in Articles 5 and 6 is submitted. | 1. The orphan medicinal product sponsor shall submit an application for the designation of the orphan medicinal product to the Agency at any stage of the development of the medicinal product before the application for marketing authorisation referred to in Articles 5 and 6 is submitted. |
| Text proposed by the Commission | Amendment |
|---|---|
| The application of the orphan medicine sponsor shall be accompanied by the following particulars and documentation: | The application for the designation of the orphan medicinal product shall be accompanied by the following particulars and documentation: |
| Text proposed by the Commission | Amendment |
|---|---|
| The application of the orphan medicine sponsor shall be accompanied by the following particulars and documentation: | The application for the designation of the orphan medicinal product shall be accompanied by the following particulars and documentation: |
| Text proposed by the Commission | Amendment |
|---|---|
| (d) justification that the criteria laid down in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) are fulfilled and a description of the stage of development, including the expected therapeutic indication. | (d) justification that the criteria laid down in Article 63(1) are fulfilled and a description of the stage of development, including the expected therapeutic indication. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. The Agency shall, in consultation with the Member States, the Commission and interested parties, draw up detailed guidelines on the required procedure, format and content of applications for designation and for the transfer of the orphan designation pursuant to Article 65. | 3. The Agency shall verify the validity of the application and share its draft scientific conclusions with the applicant. The applicant shall be invited to provide their observations on the draft conclusions.The Agency shall, in consultation with the Member States, the Commission and interested parties, draw up detailed guidelines on the required procedure, format and content of applications for designation and for the transfer of the orphan designation pursuant to Article 65. |
| Text proposed by the Commission | Amendment |
|---|---|
| The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. | The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. |
| Within the timelines for adoption of a decision foreseen in paragraph 3, the Agency shall transmit its scientific conclusions to the applicant. | |
| Within 30 days of receipt of the scientific conclusions, the sponsor may submit to the Agency a written request, citing detailed grounds, for a re-examination. | |
| Within 30 days following receipt of a request for re-examination, the Agency shall confirm or revise its previous scientific conclusions.Where the Agency considers it necessary, it may consult the Committee for Medicinal Products for Human Use or the appropriate working parties when re-examining the above mentioned scientific conclusions. | |
| If, within the 30-day period referred to in subparagraph 3, the applicant does not request re-examination, the scientific conclusions shall become definitive. | |
| The Agency shall adopt a decision within a period not exceeding 10 days following the date on which the scientific conclusions have become definitive. | |
| The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. | The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) within 90 days of the receipt of a valid application. |
| Within the timelines for adoption of a decision foreseen in subparagraph 1, the Agency shall transmit its scientific conclusions to the applicant. | |
| Within 30 days of receipt of the scientific conclusions, the sponsor may submit to the Agency a written request, citing detailed grounds, for a re-examination. | |
| Within 30 days following receipt of a request for re-examination, the Agency shall confirm or revise its previous scientific conclusions.Where the Agency considers it necessary, it may consult the Committee for Medicinal Products for Human Use or the appropriate working parties when re-examining the above mentioned scientific conclusions. | |
| If, within the 30-day period referred to in subparagraph 3, the applicant does not request re-examination, the scientific conclusions shall become definitive. | |
| The Agency shall adopt a decision within a period not exceeding 10 days following the date on which the scientific conclusions have become definitive | |
| The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. | The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant |
| Text proposed by the Commission | Amendment |
|---|---|
| The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. | The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. | The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. | The Agency shall adopt a decision granting or refusing the orphan designation based on the criteria referred to in Article 63(1) or in the relevant adopted in accordance with Article 63(2) within 90 days of the receipt of a valid application. The application is considered valid if it includes all the particulars and documentation referred to in paragraph 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| The decision together with the Annexes referred to in this paragraph shall be notified to the applicant. | The Agency shall adopt a decision within a period not exceeding 10 days following the date on which the scientific conclusions have become definitive. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. Decisions of the Agency on granting or refusing the orphan designation shall be made public after deletion of any information of a commercially confidential nature. | 5. Decisions of the Agency and a summary of consultation referred to in paragraph 4 on granting or refusing the orphan designation shall be made public after deletion of any information of a commercially confidential nature. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c a) detailed reason(s) for the transferring of the orphan designation |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan designation shall be valid for seven years. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan designation shall be valid for seven years. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan designation shall be valid for seven years. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan designation shall be valid for seven years. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan designation shall be valid for seven years. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. | 1. An orphan designation shall be valid from the day of the adoption of the decision granting the orphan designation by the Agency. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. |
Limiting the validity of the OD will disproportionally impact smaller companies, who often request the OD early-on in the development to secure additional funding. There is also little data to support that shortening the duration of the OD will accelerate development.According to data, the average time from orphan designation to marketing authorisation for mature companies was 4.7 years and 7.3 years for small biotech companies. In cases where the OD is transferred, the time to marketing authorisation was longer on average.
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan designation shall be valid for seven years. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. | 1. An orphan designation shall be valid from the day of the adoption of the decision granting the orphan designation by the Agency. During this period, the orphan medicine sponsor shall be eligible for incentives referred to in Article 68. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. By way of derogation from paragraph 1, on the basis of a justified request of the orphan medicine sponsor, the Agency may extend the validity, where the orphan medicine sponsor can provide evidence that the relevant studies supporting the use of the designated orphan medicinal product in the applied conditions are ongoing and promising with regard to the filing of a future application. Such an extension shall be limited in time, taking into account the expected remaining time needed to file an application for marketing authorisation. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. By way of derogation from paragraph 1, on the basis of a justified request of the orphan medicine sponsor, the Agency may extend the validity, where the orphan medicine sponsor can provide evidence that the relevant studies supporting the use of the designated orphan medicinal product in the applied conditions are ongoing and promising with regard to the filing of a future application. Such an extension shall be limited in time, taking into account the expected remaining time needed to file an application for marketing authorisation. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. By way of derogation from paragraph 1, on the basis of a justified request of the orphan medicine sponsor, the Agency may extend the validity, where the orphan medicine sponsor can provide evidence that the relevant studies supporting the use of the designated orphan medicinal product in the applied conditions are ongoing and promising with regard to the filing of a future application. Such an extension shall be limited in time, taking into account the expected remaining time needed to file an application for marketing authorisation. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. By way of derogation from paragraph 1, on the basis of a justified request of the orphan medicine sponsor, the Agency may extend the validity, where the orphan medicine sponsor can provide evidence that the relevant studies supporting the use of the designated orphan medicinal product in the applied conditions are ongoing and promising with regard to the filing of a future application. Such an extension shall be limited in time, taking into account the expected remaining time needed to file an application for marketing authorisation. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. By way of derogation from paragraph 1, on the basis of a justified request of the orphan medicine sponsor, the Agency may extend the validity, where the orphan medicine sponsor can provide evidence that the relevant studies supporting the use of the designated orphan medicinal product in the applied conditions are ongoing and promising with regard to the filing of a future application. Such an extension shall be limited in time, taking into account the expected remaining time needed to file an application for marketing authorisation. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. By way of derogation from paragraph 1, on the basis of a justified request of the orphan medicine sponsor, the Agency may extend the validity, where the orphan medicine sponsor can provide evidence that the relevant studies supporting the use of the designated orphan medicinal product in the applied conditions are ongoing and promising with regard to the filing of a future application. Such an extension shall be limited in time, taking into account the expected remaining time needed to file an application for marketing authorisation. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. By way of derogation from paragraph 1, where an orphan designation is valid at the time when a marketing authorisation for an orphan medicinal product has been submitted in accordance with Article 5, the orphan designation shall remain valid until a decision is adopted by the Commission in accordance with Article 13(2). | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. By way of derogation from paragraph 1, where an orphan designation is valid at the time when a marketing authorisation for an orphan medicinal product has been submitted in accordance with Article 5, the orphan designation shall remain valid until a decision is adopted by the Commission in accordance with Article 13(2). | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. By way of derogation from paragraph 1, where an orphan designation is valid at the time when a marketing authorisation for an orphan medicinal product has been submitted in accordance with Article 5, the orphan designation shall remain valid until a decision is adopted by the Commission in accordance with Article 13(2). | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. By way of derogation from paragraph 1, where an orphan designation is valid at the time when a marketing authorisation for an orphan medicinal product has been submitted in accordance with Article 5, the orphan designation shall remain valid until a decision is adopted by the Commission in accordance with Article 13(2). | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. An orphan designation ceases to be valid once an orphan medicine sponsor has obtained a marketing authorisation for the relevant medicinal product in accordance with Article 13(2). | 4. An orphan designation ceases to be valid once an orphan medicine sponsor has obtained a marketing authorisation for the relevant medicinal product in accordance with Article 13(2). An orphan designation shall however remain valid in case the indication of the initial marketing authorisation addresses only a subset of the population affected by the designated orphan condition or where the orphan medicinal product sponsor can provide evidence that studies supporting the use of the designated orphan medicinal product are planned or ongoing with respect to additional indications within the scope of the designated condition / orphan designation. |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. An orphan designation ceases to be valid once an orphan medicine sponsor has obtained a marketing authorisation for the relevant medicinal product in accordance with Article 13(2). | 4. An orphan designation ceases to be valid once an orphan medicine sponsor has obtained a marketing authorisation for the relevant medicinal product in accordance with Article 13(2). However, when the original marketing authorization only addresses part of the population affected by the designated orphan condition, the orphan designation shall remain valid. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. At any time, an orphan designation may be withdrawn at the request of the orphan medicine sponsor. | 5. At any time, an orphan designation may be withdrawn at the request of the orphan medicine sponsor. The orphan medicine sponsor may provide a reasoned justification for the withdrawal request which shall be made publicly available. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. At any time, an orphan designation may be withdrawn at the request of the orphan medicine sponsor. | 5. At any time, an orphan designation may be withdrawn at the request of the orphan medicine sponsor. The orphan medicine sponsor may provide a reasoned justification for the withdrawal request which shall be made publicly available. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c a) the stage of development; |
| Text proposed by the Commission | Amendment |
|---|---|
| (f a) any request and related decision under article 66 (2). |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The orphan medicine sponsor may, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: | 1. The orphan medicine sponsor shall, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The orphan medicine sponsor may, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: | 1. The orphan medicine sponsor shall, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The orphan medicine sponsor may, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: | 1. The orphan medicine sponsor shall, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The orphan medicine sponsor may, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: | 1. The orphan medicine sponsor shall, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The orphan medicine sponsor may, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: | 1. The orphan medicine sponsor will, prior to the submission of an application for marketing authorisation, request advice from the Agency on the following: |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) the conduct of the various tests and trials necessary to demonstrate the quality, safety and efficacy of the medicinal product, as referred to Article 138(1), second subparagraph, point (p); | (a) the conduct of the various tests and trials necessary to demonstrate the quality, safety, efficacy and environmental impact of the medicinal product, as referred to Article 138(1), second subparagraph, point (p); |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. | 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings and not-for-profit organisations provided for in framework programmes for research and technological development. For the purpose of paragraph 2, the definitions set out in Article 58a paragraph 1 of [revised Directive 2001/83/EC] shall apply. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. | 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings and not-for-profit entities, such as for example the European Medicine Facility as established in article 40a, provided for in framework programmes for research and technological development. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. | 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings and entities not engaged in economic activity provided for in framework programmes for research and technological development. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. | 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings and not-for-profit entities provided for in framework programmes for research and technological development. |
Not-for-profit entities can play an important role in developing innovative treatments (e.g. advanced therapy medicinal products, which are orphan medicinal products) and improving their access to cancer treatment patents at a fair price.
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. | 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings and not-for-profit entities provided for in framework programmes for research and technological development. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings provided for in framework programmes for research and technological development. | 2. Medicinal products designated as orphan medicinal products under the provisions of this Regulation shall be eligible for incentives made available by the Union and by the Member States to support research into, and the development and availability of, orphan medicinal products and in particular aid for research for small- and medium-sized undertakings and not-for-profit entities provided for in framework programmes for research and technological development. |
| Text proposed by the Commission | Amendment |
|---|---|
| For the purpose of paragraph 2, the definitions set out in Article 58a paragraph 1 of [revised Directive 2001/83/EC] shall apply. |
| Text proposed by the Commission | Amendment |
|---|---|
| For the purpose of paragraph 2, the definitions set out in Article 58a paragraph 1 of [revised Directive 2001/83/EC] shall apply. |
| Text proposed by the Commission | Amendment |
|---|---|
| In addition, the applicant shall demonstrate that the medicinal product has been granted an orphan designation and that the criteria set out in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) are fulfilled for the therapeutic indication sought. | In addition, the applicant shall demonstrate that the medicinal product has been granted an orphan designation and that the criteria set out in Article 63(1) are fulfilled for the therapeutic indication sought. |
| Text proposed by the Commission | Amendment |
|---|---|
| Where appropriate, the applicant shall provide relevant evidence to demonstrate that the medicinal product addresses a high unmet medical need as specified in Article 70(1). | Where appropriate, the applicant shall provide relevant evidence to demonstrate that the medicinal product constitutes a breakthrough orphan medicinal product in accordance with in Article 70(1). |
| Text proposed by the Commission | Amendment |
|---|---|
| The Committee for Medicinal Products for Human Use shall assess whether the medicinal product fulfils the requirements set out in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2). In the situation referred in paragraph 2, subparagraph 2, that Committee shall also assess whether the medicinal product addresses a high unmet medical need as specified in Article 70(1). | The Committee for Medicinal Products for Human Use shall assess whether the medicinal product fulfils the requirements set out in Article 63(1). In the situation referred in paragraph 2, subparagraph 2, that Committee shall also assess whether the medicinal product addresses a high unmet medical need as specified in Article 70(1). |
| Text proposed by the Commission | Amendment |
|---|---|
| The Committee for Medicinal Products for Human Use shall assess whether the medicinal product fulfils the requirements set out in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2). In the situation referred in paragraph 2, subparagraph 2, that Committee shall also assess whether the medicinal product addresses a high unmet medical need as specified in Article 70(1). | The Committee for Medicinal Products for Human Use shall assess whether the medicinal product fulfils the requirements set out in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2). In the situation referred in paragraph 2, subparagraph 2, that Committee shall also assess whether the medicinal product constitutes a breakthrough orphan medicinal product in accordance with in Article 70(1). |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. The orphan marketing authorisation shall cover only those therapeutic indications, which fulfil the requirements set out in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2) at the time when the orphan marketing authorisation is granted. | 4. The orphan marketing authorisation shall cover only those therapeutic indications, which fulfil the requirements set out in Article 63(1) at the time when the orphan marketing authorisation is granted. |
| Text proposed by the Commission | Amendment |
|---|---|
| 6. An applicant may submit an application for a separate marketing authorisation for other indications which do not fulfil the requirements set out in Article 63(1) or in the relevant delegated acts adopted in accordance with Article 63(2). | 6. An applicant may submit an application for a separate marketing authorisation for other indications which do not fulfil the requirements set out in Article 63(1). |
| Text proposed by the Commission | Amendment |
|---|---|
| 6 a. As laid down in Article 17, authorised products shall be subject to re-evaluation after 5 years. In cases of orphan medicinal products, the Committee for Medicinal Products for Human use shall in addition to the product’s safety, efficacy and environmental impact also review the criteria in set in Article 63 and assess the profitability of the product, taking into account all authorised indications, as laid down in Article 72. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
The criteria set out in this article are already in a large extend addressed in the requirements of unmet medical needs (with the exemption of advancement in therapeutic which are exceptional addressed in a different article). Criteria for high met medical need for orphan medicines as a distinct category risk undermining unmet medical needs by suggesting some needs are less important. In this regard, a definition of unmet medical needs would need a more holistic approach and better understanding to not undermine the purpose of this regulation with regard to these needs, medicines and treatments.
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
Frédérique Ries, Catherine Amalric, Susana Solís Pérez, Max Orville, Andreas Glück, Ondřej Knotek, Billy Kelleher, Erik Poulsen
| Text proposed by the Commission | Amendment |
|---|---|
| Article 70 | deleted |
| Orphan medicinal products addressing a high unmet medical need | |
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | |
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | |
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. |
95% of people living with a rare disease do not have an approved therapy available to them (European Commission). In this context, creating an artificial hierarchy of patients and their needs, or considering that some are more "meaningful", is innaprorpiate and does not reflect the reality of rare diseases. See amendment on article 71 for alternative proposal.
| Text proposed by the Commission | Amendment |
|---|---|
| Orphan medicinal products addressing a high unmet medical need | Breakthrough Designated Orphan medicinal products |
| Text proposed by the Commission | Amendment |
|---|---|
| Orphan medicinal products addressing a high unmet medical need | Breakthrough Designated Orphan Medicinal Products |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | deleted |
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | |
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | 1. An orphan medicinal product shall be designated as a breakthrough orphan medicinal product where it can be demonstrated at the moment of designation that the one of the following requirements are met: |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. An orphan medicinal product shall be considered as addressing a high unmet medical need where it fulfils the following requirements: | 1. An orphan medicinal product shall be designated as a breakthrough orphan medicinal product where it can be demonstrated at the moment of designation that the following requirements are met: |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | (a) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorised in the Union, or; |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | (a) There exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorised in the Union, or |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | (a) there is no medicinal product authorised in the Union for such condition, or; |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) there is no medicinal product authorised in the Union for such condition orwhere, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; | (a) there is no medicinal product authorised in the Union for such condition or where, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement; and |
| Text proposed by the Commission | Amendment |
|---|---|
| (a a) despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant clinical benefit based on improved efficacy, safety and contribution to patient care, will bring a therapeutic advancement to a part of the relevant patient population; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) Where, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product uses a new and unique mechanism of action and the use of the medicinal product results in meaningful prevention of or reduction in disease morbidity or mortality or a major contribution to patient care for the relevant population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) where, despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product uses a new and unique mechanism of action and the use of the medicinal product results in meaningful prevention of or reduction in disease morbidity or mortality or a major contribution to patient care for the relevant population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality or in a meaningful positive impact on quality of life for the relevant patient population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity, mortality, severity or long term side effects for the relevant patient population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) the use of the medicinal product results in a meaningful reduction in disease morbidity, acute or long-term toxicity or mortality for the relevant patient population. |
A medicinal product should also be considered as addressing a UMN or high UMN when it reduces acute or long-term toxicity for children with cancer
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) the use of the orphan medicinal product results in a substantial reduction in disease morbidity or mortality for the relevant patient population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) the use of the orphan medicinal product results in a meaningful reduction in disease morbidity or mortality for the relevant patient population. | (b) the use of the orphan medicinal product results in a reduction in disease morbidity or mortality for the relevant patient population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b a) the use of the medicinal product results in a substantial improvement of patients' quality of life. |
A medicinal product should also be considered as addressing a UMN or high UMN when it improves quality of life for patients.
| Text proposed by the Commission | Amendment |
|---|---|
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 2. A medicinal product for which an application has been submitted in accordance with Article 13 of [revised Directive 2001/83/EC] shall not be considered as addressing a high unmet medical need. | 2. Breakthrough designated orphan medicinal products shall be entitled to enhanced scientific and regulatory support pursuant to Article 60 of this Regulation. The Commission shall adopt the necessary provisions for implementing this Article by means of implementing acts in accordance with the procedure laid down in Article 173(2). |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. | 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies, as well as the stakeholders such as representatives of patients' organisations in the relevant disease areas, healthcare professionals, orphan medicinal product sponsors, representatives of pharmaceutical industry and other relevant stakeholders referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. | 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies and other relevant stakeholders referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. | 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission, all relevant stakeholders and the authorities or bodies referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. | 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission, the authorities, bodies and stakeholders referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission and the authorities or bodies referred to in Article 162. | 3. Where the Agency adopts scientific guidelines for the application of this Article, it shall consult the Commission, the authorities and bodies referred to in Article 162. |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. Where an orphan marketing authorisation is granted and without prejudice to intellectual property law, the Union and the Member States shall not grant a marketing authorisation or extend an existing marketing authorisation, for the same therapeutic indication, in respect of a similar medicinal product for the duration of market exclusivity set out in paragraph 2. | 1. Where an orphan marketing authorisation is granted and without prejudice to intellectual property law, a similar medicinal product authorized for the same therapeutic indication shall not be placed on the market for the duration of market exclusivity set out in paragraph 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) twelve years for orphan medicinal products for whose indication the Union has not approved a satisfactory treatment method; |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) eight years for orphan medicinal products other than those referred to in points (b), (ba) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) nine years for orphan medicinal products other than those referred to in points (b), (c) and (ca); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) nine years for orphan medicinal products other than those referred to in points (b), (c) and (ca); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) twelve years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) twelve years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) twelve years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) twelve years for orphan medicinal products other than those referred to in points (b) and (c); |
It is important to further facilitate for further investment in areas where the scientific challenges are acute. Improved and strengthened incentives will strengthen the competitiveness in the EU and ensure that the EU is a pioneer to development and research and develop new, cutting-edge medicines in different areas. Hence, to condition an enhanced baseline protection to objective criteria is needed, since it would provide operators with sufficient certainty to undertake investments and in particularly during challenging and high-risk circumstances.
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) twelve years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) eight years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) seven years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) ten years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) ten years for orphan medicinal products other than those referred to in points (b) and (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) ten years for orphan medicinal products other than those referred to in points (b) and (c); |
The amendment proposes to build on the current OMP Regulation – with a 10-year OME baseline – and adapt the COM proposal on modulation to better reflect the realities of the industry landscape, in particular investments decisions which are made years before marketing authorisation. The COM and Rapporteur proposal to reduce the baseline OME to 9 and 8 years respectively, together with the introduction of criteria-based extensions will both reduce appetite to support early development and clarity of investment horizon.
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) ten years for orphan medicinal products other than those referred to in point (b); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) ten years for orphan medicinal products other than those referred to in point (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (a) nine years for orphan medicinal products other than those referred to in points (b) and (c); | (a) Ten years for orphan medicinal products other than those referred to in point (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) thirteen years for orphan medicinal products which satisfy any of the following criteria: |
| i. there is no medicinal product authorised in the Union for such condition or where | |
| ii. even though the Union has authorized medicinal products for such condition, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will result in exceptional therapeutic advancement or iii. the condition affects not more than 0,5 in 10,000 persons in the Union when the application for an orphan designation is submitted. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) thirteen years for orphan medicinal products which fulfil one of the following requirements: |
| i. there is no medicinal product authorised in the Union for such condition or where | |
| ii. despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement or | |
| iii. the condition affects not more than 0,5 in 10,000 persons in the Union when the application for an orphan designation is submitted. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) ten years for orphan medicinal products if: |
| 1. the Union has authorised fewer than three (3) orphan medicinal products for the indication in question, or; | |
| 2. notwithstanding any authorisations for medicinal products for the condition in question, no orphan medicinal product has received EU authorisation for part of the target population or subsets thereof as regards the therapeutic indication of the new medicinal product, or; | |
| 3. the Union has authorised an orphan medicinal product for use according to its indication, but that orphan medicinal product either has a new mechanism of application or is a new technology; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) thirteen years for orphan medicinal products which fulfil one of the following requirements: |
| i. there is no medicinal product authorised in the Union for such condition or where | |
| ii. despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement or | |
| iii. the condition affects not more than 0,5 in 10,000 persons in the Union when the application for an orphan designation is submitted. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) twelve years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; |
| The market exclusivity for the orphan indication shall not preclude that generics and biosimilars can enter the market for other uses of the medicinal product that are not protected by data and market protection, patents, or supplementary protection certificates. |
Rare diseases, especially those with very low prevalence, often pose unique scientific and clinical challenges. To encourage companies to invest in research for these conditions, additional incentives, such as extended market exclusivity and research grants, are vital. A graduation system to provide different levels of incentives depending on factors to best address the unmet needs of people living with a rare disease should be introduced. For example, targeting very to ultra-rare conditions, or those with no therapeutic option yet, may constitute a basis for a reward.
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) therteen years for orphan medicinal products that are the first for that indication, that represent an important advance or that involve treatment for diseases of very low prevalence |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) twelve years for orphan medicinal products where no satisfactory treatment has been approved in the Union for the indication in question. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) twelve years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) twelve years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) twelve years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) eight years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) thirteen years for orphan medicinal products and that one of the following requireiments can be fullfilled: |
It is important to further facilitate for further investment in areas where the scientific challenges are acute. Improved and strengthened incentives will strengthen the competitiveness in the EU and ensure that the EU is a pioneer to development and research and develop new, cutting-edge medicines in different areas. Hence, to condition an enhanced baseline protection to objective criteria is needed, since it would provide operators with sufficient certainty to undertake investments and in particularly during challenging and high-risk circumstances.
| Text proposed by the Commission | Amendment |
|---|---|
| (b) ten years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70; | (b) twelve years for breakthrough orphan medicinal products as referred to in Article 70; |
| Text proposed by the Commission | Amendment |
|---|---|
| i) no medicinal product in the Union are authorised for such condition; |
It is important to further facilitate for further investment in areas where the scientific challenges are acute. Improved and strengthened incentives will strengthen the competitiveness in the EU and ensure that the EU is a pioneer to development and research and develop new, cutting-edge medicines in different areas. Hence, to condition an enhanced baseline protection to objective criteria is needed, since it would provide operators with sufficient certainty to undertake investments and in particularly during challenging and high-risk circumstances.
| Text proposed by the Commission | Amendment |
|---|---|
| ii) regardless if medicinal products in the Union are being authorised for such condition, the applicant can demonstrate that the orphan medicinal product (apart of having a demonstrated benifit) will contribute to exceptional advancement for therapeutic; |
It is important to further facilitate for further investment in areas where the scientific challenges are acute. Improved and strengthened incentives will strengthen the competitiveness in the EU and ensure that the EU is a pioneer to development and research and develop new, cutting-edge medicines in different areas. Hence, to condition an enhanced baseline protection to objective criteria is needed, since it would provide operators with sufficient certainty to undertake investments and in particularly during challenging and high-risk circumstances.
| Text proposed by the Commission | Amendment |
|---|---|
| iii) the condition affects no more than 0,5 in 10,000 persons in the European Union when the application designated for an orphan has been submitted. |
It is important to further facilitate for further investment in areas where the scientific challenges are acute. Improved and strengthened incentives will strengthen the competitiveness in the EU and ensure that the EU is a pioneer to development and research and develop new, cutting-edge medicines in different areas. Hence, to condition an enhanced baseline protection to objective criteria is needed, since it would provide operators with sufficient certainty to undertake investments and in particularly during challenging and high-risk circumstances.
| Text proposed by the Commission | Amendment |
|---|---|
| (b a) Ten years for orphan medicinal products where one of the following criteria applies: | |
| i. fewer than three orphan medicinal products have been approved in the Union for the indication in question; | |
| ii. despite medicinal products being authorised for the indication in question, none has been approved in the Union for the relevant subpopulation that is covered by the therapeutic indication of the new medicinal product; | |
| iii. an orphan medicinal product has been approved in the Union for the indication, but the new orphan medical product will represent a new mechanism of action or technology, and will result in significant reduction in disease morbidity or mortality for the relevant patient population, or a major contribution to the quality of life of the relevant population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (b a) ten years for an orphan medicinal product where: | |
| 1. fewer than three orphan medicinal products have been approved in the Union for the indication in question, or; | |
| 2. despite medical products being authorised for such a condition, no orphan medicinal product has been approved in the Union for a part of the target population or subpopulation that is covered by the therapeutic indication for the new medicinal product, or; | |
| 3. an orphan medicinal product has been approved in the Union for the indication, but the orphan medical product will represent a new mechanism of action or technology; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b a) twelve years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70 in the paediatric population; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b a) twelve years for orphan medicinal products addressing an unmet medical need as referred to in Article 70 in the paediatric population; |
| Text proposed by the Commission | Amendment |
|---|---|
| (b b) eight years for an orphan medicinal product that does not fall under paragraphs (b), (ba) or (bb); |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | deleted |
Products marketed under Article 13 are based on bibliographic data only, meaning the MA holder did not run any additional clinical trial and based their finding on existing available research. Given that the product would generate profit by being sold, we do not find it reasonable to provide market exclusivity in this case
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) seven years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
It is important to further facilitate for further investment in areas where the scientific challenges are acute. Improved and strengthened incentives will strengthen the competitiveness in the EU and ensure that the EU is a pioneer to development and research and develop new, cutting-edge medicines in different areas. Hence, to condition an enhanced baseline protection to objective criteria is needed, since it would provide operators with sufficient certainty to undertake investments and in particularly during challenging and high-risk circumstances.
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) seven years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) seven years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) seven years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) seven years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) seven years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) six years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. | (c) five years for orphan medicinal products which have been authorised in accordance with Article 13 of [revised Directive 2001/83/EC]. |
| The market exclusivity for the orphan indication shall not preclude that generics and biosimilars can enter the market for other uses of the medicinal product that are not protected by data and market protection, patents, or supplementary protection certificates. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c a) twelve years for orphan medicinal products addressing requirements set in Article 70, paragraph 1 point (a) and (b) in the paediatric population. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c a) twelve years for orphan medicinal products addressing a high unmet medical need as referred to in Article 70 in the paediatric population; |
Some paediatric cancers do not exist in adults. Therefore the original path of first in adult second in child through PIPs does not work. Therefore there is a need for first-in-child incentive.
| Text proposed by the Commission | Amendment |
|---|---|
| (ca) eight years for orphan medicinal products that are not referred to in points (a), (b) or (c); |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall not benefit from separate market exclusivity periods. The duration of the market exclusivity shall start from the date when the first orphan marketing authorisation was granted in the Union. | 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, other than in cases foreseen in Article 72, paragraph 2, subparagraph 2, those authorisations shall not benefit from separate market exclusivity periods. The duration of the market exclusivity shall start from the date when the first orphan marketing authorisation was granted in the Union. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall not benefit from separate market exclusivity periods. The duration of the market exclusivity shall start from the date when the first orphan marketing authorisation was granted in the Union. | 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall benefit from separate market exclusivity periods whose duration is outlined in paragraph 2. The duration of each market exclusivity period shall start from the date when the corresponding orphan marketing authorisation was granted in the Union. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall not benefit from separate market exclusivity periods. The duration of the market exclusivity shall start from the date when the first orphan marketing authorisation was granted in the Union. | 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall benefit from separate market exclusivity periods, provided a market exclusivity period was still in force when the application for marketing authorisation was submitted. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall not benefit from separate market exclusivity periods. The duration of the market exclusivity shall start from the date when the first orphan marketing authorisation was granted in the Union. | 3. Where a marketing authorisation holder holds more than one orphan marketing authorisations for the same active substance, those authorisations shall benefit from separate market exclusivity periods, provided that a market exclusivity period was still in force when the application for marketing authorisation was submitted. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3 a. Where the orphan marketing authorisation holders benefit from market exclusivity for an orphan medicinal product under paragraph 1 of this Article, they must demonstrate that they meet the requirements set in paragraph 1 of Article 72a of this Regulation. |
| Text proposed by the Commission | Amendment |
|---|---|
| (c a) a compulsory license has been granted in accordance with [Regulation on compulsory licensing for crisis management and amending Regulation (EC) 816/2006]. |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. The submission, validation and assessment of the application for the marketing authorisation and granting the marketing authorisation for a generic or biosimilar product to the reference medicinal product for which market exclusivity has expired, shall not be prevented by the market exclusivity of a similar product to the reference medicinal product. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 5. The submission, validation and assessment of the application for the marketing authorisation and granting the marketing authorisation for a generic or biosimilar product to the reference medicinal product for which market exclusivity has expired, shall not be prevented by the market exclusivity of a similar product to the reference medicinal product. | 5. The submission, validation and assessment of the application for the marketing authorisation and granting the marketing authorisation for a generic or biosimilar product to the reference medicinal product, shall not be prevented by the market exclusivity of a similar product to the reference medicinal product. |
| Text proposed by the Commission | Amendment |
|---|---|
| 6. The market exclusivity of the orphan medicinal product shall not prevent the submission, validation and assessment of an application for a marketing authorisation for a similar medicinal product, including generics and biosimilars, where the remainder of the duration of the market exclusivity is less than two years. | 6. The market exclusivity of the orphan medicinal product shall not prevent the submission, validation, assessment of an application for and granting of a marketing authorisation for a similar medicinal product, including generics and biosimilars, where the remainder of the duration of the initial market exclusivity is less than two years. |
| Text proposed by the Commission | Amendment |
|---|---|
| 6. The market exclusivity of the orphan medicinal product shall not prevent the submission, validation and assessment of an application for a marketing authorisation for a similar medicinal product, including generics and biosimilars, where the remainder of the duration of the market exclusivity is less than two years. | 6. The market exclusivity of the orphan medicinal product shall not prevent the submission, validation, assessment or granting of an application for a marketing authorisation for a similar medicinal product, including generics and biosimilars, where the remainder of the duration of the market exclusivity is less than two years. |
| Text proposed by the Commission | Amendment |
|---|---|
| 7. Where the Agency adopts scientific guidelines for the application of paragraphs 1 and 4, it shall consult the Commission. | 7. The Agency shall adopt scientific guidelines for the application of paragraphs 1 and 4, it shall consult the Commission. |
| Text proposed by the Commission | Amendment |
|---|---|
| Article 72 | deleted |
| Prolongation of market exclusivity | |
| 1. | |
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | |
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | |
| 2. | |
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | |
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | |
| 3. The orphan medicinal products which benefit from the prolongation of market exclusivity referred to in the paragraph 2 shall not benefit from the additional period of data protection referred to in Article 81(2), point (d), of [revised Directive 2001/83/EC]. | |
| 4. Article 71(3) equally applies to the prolongations of market exclusivity referred to in paragraphs 1 and 2. |
| Text proposed by the Commission | Amendment |
|---|---|
| Prolongation of market exclusivity | Prolongation and reduction of market exclusivity period |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. |
| Text proposed by the Commission | Amendment |
|---|---|
| 1. The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
See amendment to Article 81(2), point (a), and Article 82(1) of the draft report on the revised Directive 2001/83/EC.
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
Tying incentive systems to market access is not the right approach and leads to uncertainty among producers. Supply of medical medicinal product in all Member States can also be achieved differently, for example by an obligation to submit an application for pricing and reimbursement in all Member States.
| Text proposed by the Commission | Amendment |
|---|---|
| The periods of market exclusivity referred to in Article 71, paragraph 2, points (a) and (b), shall be prolonged by 12 months, where the orphan marketing authorisation holder can demonstrate that the conditions referred to in Article 81(2), point (a), and Article 82(1) [of revised Directive 2001/83/EC] are fulfilled. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| The procedures set out in Articles 82(2) to (5) [of revised Directive 2001/83/EC] shall accordingly apply to the prolongation of market exclusivity. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 1 a. The period of market exclusivity shall be prolonged by an additional 24 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. If the newly approved therapeutic indication meets one of the requirements listed in Article 71(2) point (b), and where the first orphan marketing authorisation was not granted a period of market exclusivity as referred in Article 71(2) point (b), the period of market exclusivity shall be prolonged by 36 months in total. |
| Text proposed by the Commission | Amendment |
|---|---|
| 1 a. The period of market exclusivity shall be prolonged by 24 months for orphan medicinal products referred to in Article 71, paragraph 2, point (a), if one of its therapeutic indications fulfils one of the following requirements: | |
| i. there is no medicinal product authorised in the Union for such condition or; | |
| ii. despite medicinal products being authorised for such condition in the Union, the applicant demonstrates that the orphan medicinal product, in addition to having a significant benefit, will bring exceptional therapeutic advancement or; | |
| iii. the condition affects not more than 0,5 in 10,000 persons in the Union when the application for an orphan designation is submitted. When applying to new therapeutic indications, this prolongation shall apply for indications approved at least two years before the end of the exclusivity period. |
The HUMN incentive should also apply to follow-on indications in order to account for the reality of science: indications aiming to address underserved areas can be developed after the initial MA. Such an extension is critical to effectively steer R&D in all areas of UMN. This is also to align with the definition of Unmet Medical Need under Article 83 of the Directive that explicitly refers to the indications of the products. For High UMN, the definition should include diseases with a very low prevalence (<0.5/10,000) as alternative criteria to first-in-condition medicines or those providing exceptional therapeutic advancement. There is indeed a need to further incentivize research and development in diseases that affect such small populations, for which there is typically less investment due to the risky, lengthy and costly nature of such research.
| Text proposed by the Commission | Amendment |
|---|---|
| 2. The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | deleted |
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 36 months for orphan medicinal products referred to in Article 71(2), points (a), (b) and (c), if at least four years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for a different orphan condition. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 36 months for orphan medicinal products referred to in Article 71(2), points (a),(b) and (c a), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for a new therapeutic indication for a different orphan condition. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 24 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. If the newly approved therapeutic indication meets one of the requirements listed in Article 71(2) point (b), and where the first orphan marketing authorisation was not granted a period of market exclusivity as referred in Article 71(2) point (b), the period of market exclusivity shall be prolonged by 36 months in total. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 24 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. If the recently approved therapeutic indication satisfies one of the criteria mentioned in Article 71(2) point (b) and a period of market exclusivity was not granted for the first orphan marketing authorization as mentioned in Article 71(2) point (b), the period of market exclusivity shall be extended by a total of 36 months. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 24 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. |
it is proposed to increase the incentive for new indication to 24 months and to implement a decrease in additional OME to 12 months after 2 new indications for different orphan conditions. The overall cap to OME introduced will also prevent misuse. Considering in practice very few marketing authorisations extend beyond 2 to 3 indications, the proposal would reward continuous investments in a specific therapy that could be extended to new patient population. The amendments below also introduces the choice to the marketing authorisation holders as regards the completion of a paediatric investigation plan (PIP). With the amendment, sponsors could decide between the extension of supplementary protection certificate (SPC) or OME. This would ensure that all sponsors complete PIP even when they would not be eligible for a SPC extension.
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 24 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 24 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. |
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 6 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. |
We can only accept these provisions if exclusivity periods established in Article 71 are shortened, in no way we would agree going beyond (current) accumulated 11 years of exclusivity
| Text proposed by the Commission | Amendment |
|---|---|
| The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a) and (b), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. | The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a), (b) and (ba), if at least two years before the end of the exclusivity period, the orphan marketing authorisation holder obtains a marketing authorisation for one or more new therapeutic indications for a different orphan condition. |
| Text proposed by the Commission | Amendment |
|---|---|
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | deleted |
Once a product has been approved for a specific indication, any new, additional indication or extension of the existing orphan indication, requires a separate assessment by the EMA and marketing authorisation decision by the Commission. As it is not a simple or quick process and in fact, only a few medicines have more than one orphan indication, capping the extension of market exclusivity to two years may deter sponsors from investigating in new areas of clinical development.
| Text proposed by the Commission | Amendment |
|---|---|
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| Such a prolongation may be granted twice, if the new therapeutic indications are each time for different orphan conditions. | Such a prolongation may be granted twice, if the new therapeutic indications are for different orphan conditions. |
| Text proposed by the Commission | Amendment |
|---|---|
| When the marketing authorisation holder obtains any further marketing authorisations for one or more therapeutic indications covering different orphan conditions for the same orphan medicinal product, these specific therapeutic indications shall be protected by a separate market exclusivity of three years, starting from the expiration of the market exclusivity for the entire product under Article 71, where relevant as extended under paragraphs 1 and 2 of this Article. |
| Text proposed by the Commission | Amendment |
|---|---|
| Any subsequent marketing authorisation obtained by the marketing authorisation holder for one or more new therapeutic indications for different orphan conditions shall receive a separate market exclusivity of three years, starting from the expiration date of the market exclusivity for the entire product under Article 71, where relevant as extended under paragraphs 1 and 2 of this article. |
This amendment aims at reaping the maximum benefits from the research already done by encouraging the exploration of further indications while addressing the risk of evergreening (stacking of indication protections) which delays the entry of generics.
| Text proposed by the Commission | Amendment |
|---|---|
| When the orphan marketing authorisation holder obtains any further marketing authorisations for one or more therapeutic indications relative to different orphan conditions for the same orphan medicinal product, these specific therapeutic indications shall be protected by a separate market exclusivity of three years from the expiry of the market exclusivity for the entire product pursuant to Article 71, where appropriate in accordance with Article 71(1) and (2). |
| Text proposed by the Commission | Amendment |
|---|---|
| After the orphan medical product in question first receives an authorization as stated in Article 69, the holder of an orphan marketing authorization shall be entitled to a maximum of [15] years of orphan marketing exclusivity. |
| Text proposed by the Commission | Amendment |
|---|---|
| If requested by the applicant as an option instead of the stipulated reward in Article 86 of the revised Directive, the duration of market exclusivity for orphan medicinal products, as specified in Article 71(2), points (a) and (b), will be extended by an extra 24 months. This extension applies when an application for orphan marketing authorization is submitted for a designated orphan medicinal product under the Revised Regulation, and the application incorporates the findings of all studies conducted in adherence to an agreed-upon paediatric investigation plan. The first subparagraph shall also be applicable where fulfilment of the stipulated paediatric investigation plan does not result in the approval of a pediatric indication. However, the findings from the conducted studies should be incorporated into the summary of product characteristics and, if deemed suitable, into the package leaflet of the respective medicinal product. The extension of the market exclusivity period by 24 months will be acknowledged in the marketing authorization. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2 a. The holder of an orphan marketing authorisation shall be entitled to a total maximum period of [15] years of orphan marketing exclusivity from the time the orphan medicinal product in question first obtains an authorization as defined in Article 69. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2 a. The period of market exclusivity shall be prolonged by an additional 12 months for orphan medicinal products referred to in Article 71(2), points (a), (b), and (ba) if the orphan medicinal product is not authorised for the indication in question in any third country at the time of granting the authorisation. |
This amendment aims at rewarding orphan medicinal product sponsors choosing Europe first, hereby helping European patients to access innovative treatment early.
| Text proposed by the Commission | Amendment |
|---|---|
| 2 b. As an alternative to the reward foreseen under Article 86 [of revised Directive] and upon request from the applicant, the period of market exclusivity for orphan medicinal products referred to in Article 71(2), points (a) and (b) shall be prolonged by an additional 24 months where an application for orphan marketing authorisation is submitted in respect of a designated orphan medicinal product pursuant to [Revised Regulation] and that application includes the results of all studies conducted in compliance with an agreed paediatric investigation plan. The first subparagraph shall also apply where completion of the agreed paediatric investigation plan fails to lead to the authorisation of a paediatric indication, but the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned. The 24-month extension of the period of market exclusivity will be reflected in the marketing authorisation. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2 c. An orphan medicinal product which benefits from the prolongation of market exclusivity as referred to in paragraph 4, shall not benefit from the rewards referred to in Article 86 [of revised Directive]. |
| Text proposed by the Commission | Amendment |
|---|---|
| 2 d. The limitation referred to in paragraph 3 shall not apply where the period of orphan marketing exclusivity is extended in accordance with paragraph 4 in relation to such extension. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. The orphan medicinal products which benefit from the prolongation of market exclusivity referred to in the paragraph 2 shall not benefit from the additional period of data protection referred to in Article 81(2), point (d), of [revised Directive 2001/83/EC]. | 3. Upon request from the applicant, the period of market exclusivity for orphan medicinal products referred to in Article 71(2), points (a) and (b) shall be prolonged by an additional 24 months where an application for orphan marketing authorisation is submitted in respect of a designated orphan medicinal product pursuant to [Revised Regulation] and that application includes the results of all studies conducted in compliance with an agreed paediatric investigation plan. |
| The first subparagraph shall also apply where completion of the agreed paediatric investigation plan fails to lead to the authorisation of a paediatric indication, but the results of the studies conducted are reflected in the summary of product characteristics and, if appropriate, in the package leaflet of the medicinal product concerned. The 24-month extension of the period of market exclusivity shall be reflected in the marketing authorisation. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. The orphan medicinal products which benefit from the prolongation of market exclusivity referred to in the paragraph 2 shall not benefit from the additional period of data protection referred to in Article 81(2), point (d), of [revised Directive 2001/83/EC]. | 3. Upon request from the applicant, the period of market exclusivity for orphan medicinal products referred to in Article 71(2), points (a) and (b) shall be prolonged by an additional 24 months where an application for orphan marketing authorisation is submitted in respect of a designated orphan medicinal product and that application includes the results of all studies conducted in compliance with an agreed paediatric investigation plan. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3. The orphan medicinal products which benefit from the prolongation of market exclusivity referred to in the paragraph 2 shall not benefit from the additional period of data protection referred to in Article 81(2), point (d), of [revised Directive 2001/83/EC]. | 3. The orphan medicinal products which benefit from the prolongation of market exclusivity referred to in the paragraph 2 shall not benefit from the additional period of data protection referred to in Article 81(2), point (d), of [revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3 a. The restriction mentioned in paragraph 3 shall not apply when the orphan marketing exclusivity period is prolonged as outlined in paragraph 4 concerning that extension. |
| Text proposed by the Commission | Amendment |
|---|---|
| 3 b. The extended market exclusivity mentioned in paragraph 2 does not apply to orphan medicinal products, and they will not receive the extra period of data protection outlined in Article 81(2), point (d) of the revised Directive 2001/83/EC. |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. Article 71(3) equally applies to the prolongations of market exclusivity referred to in paragraphs 1 and 2. | deleted |
| Text proposed by the Commission | Amendment |
|---|---|
| 4. Article 71(3) equally applies to the prolongations of market exclusivity referred to in paragraphs 1 and 2. | 4. An orphan medicinal product which benefits from the prolongation of market exclusivity as referred to in paragraph 3, shall not benefit from the rewards referred to in Article 86 [of revised Directive 2001/83/EC]. |
| Text proposed by the Commission | Amendment |
|---|---|
| 4 a. The total period of orphan marketing exclusivity for an orphan marketing authorisation shall not exceed twenty years from the date of the initial marketing authorisation. |
| Text proposed by the Commission | Amendment |
|---|---|
| 4 a. The market exclusivity period shall be reduced to five years if, at the end of the fifth year, it is established, in respect of the medicinal product concerned, that the criteria laid down in Article 63 are no longer met or where it is shown on the basis of available evidence that the product is sufficiently profitable not to justify maintenance of market exclusivity. The sponsor shall provide the Agency with the information necessary to re-assess the criteria laid down in Article 63 and the externally audited product-related profit margins for all authorised indications at least nine months before end of the fifth year. |
Connections
The dossier, the decisions on this text and its other versions.
No connections found for this item.
Sources & citation
Where the facts on this page come from, and how to cite it.
- Data source
- Licensed CC BY 4.0.
- Retrieved
- 25 September 2026
Cite as
European Parliament (2023). “AMENDMENTS 1062 - 1276 - Draft report Laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006”. Text, 21 November 2023. docId ENVI-AM-756135. EU Parl Watch Research. https://news.eu-parl.st-solutions.dev/texts/ENVI-AM-756135 (retrieved 25 September 2026). Data: EP Open Data API: document record, https://data.europarl.europa.eu/api/v2/documents/ENVI-AM-756135 (CC BY 4.0).
BibTeX
@misc{epw-text-envi-am-756135,
author = {{European Parliament}},
title = {{AMENDMENTS 1062 - 1276 - Draft report Laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing rules governing the European Medicines Agency, amending Regulation (EC) No 1394/2007 and Regulation (EU) No 536/2014 and repealing Regulation (EC) No 726/2004, Regulation (EC) No 141/2000 and Regulation (EC) No 1901/2006}},
year = {2023},
date = {2023-11-21},
howpublished = {\url{https://news.eu-parl.st-solutions.dev/texts/ENVI-AM-756135}},
url = {https://news.eu-parl.st-solutions.dev/texts/ENVI-AM-756135},
urldate = {2026-09-25},
publisher = {EU Parl Watch Research},
note = {Text. docId ENVI-AM-756135. Data: EP Open Data API: document record (CC BY 4.0)}
}